首页> 外文期刊>Modern Pathology >Gene expression profiling identifies p63 as a diagnostic marker for giant cell tumor of the bone
【24h】

Gene expression profiling identifies p63 as a diagnostic marker for giant cell tumor of the bone

机译:基因表达谱鉴定p63为骨巨细胞瘤的诊断标记

获取原文
           

摘要

Giant cell tumor of the bone (GCTOB) is a primary bone tumor that occurs mainly in young adults and is capable of locally aggressive growth. Its histologic appearance can resemble a number of benign and malignant tumors but no useful diagnostic marker is known currently. To identify diagnostic markers for this tumor, global gene expression profiling using cDNA microarray was performed on 6 fresh-frozen GCTOB, 3 aneurysmal bone cysts, 4 fibrous dysplasias and 12 giant cell tumors of tendon sheath/diffuse-type giant cell tumors. Unsupervised hierarchical clustering separated the tumors based on their histopathologic types, and significance analysis of microarray identified several genes including TP73L (encoding the p63 protein) that are significantly highly expressed in GCTOB relative to these other tumors. The diagnostic utility of p63 was subsequently confirmed using anti-p63 antibody on a series of 26 GCTOB, 25 aneurysmal bone cysts, 15 chondroblastomas, 13 giant cell reparative granulomas, 13 chondromyxoid fibromas, 4 brown tumors, 4 fibrous dysplasias, 53 giant cell tumors of tendon sheath/diffuse-type giant cell tumors and 385 additional mesenchymal tumors in tissue microarrays. Strong p63 nuclear staining was present in 18 of 26 (69%) GCTOB, 3 of 15 (20%) chondroblastomas and in 1 of 25 (4%) aneurysmal bone cysts while none of the other tumors commonly considered in the differential diagnosis of GCTOB showed any detectable p63 staining. Strong p63 staining is rare in bone and soft-tissue tumors in general. In contrast to the pattern of p63 staining, the majority of the chondroblastomas (70%) demonstrated S-100 immunoreactivity while only a minority of the GCTOB (8%) was immunoreactive for S-100. These findings altogether show that p63 can be used as a diagnostic marker to aid the clinical diagnosis of GCTOB.
机译:骨巨细胞瘤(GCTOB)是主要在年轻人中发生的原发性骨肿瘤,能够局部侵袭性生长。其组织学外观可类似于许多良性和恶性肿瘤,但目前尚无有用的诊断标志物。为了鉴定该肿瘤的诊断标记,对6例新鲜冷冻的GCTOB,3例动脉瘤性骨囊肿,4例纤维性异型增生和12例腱鞘/弥漫型巨细胞瘤巨细胞瘤进行了基因表达谱分析。无监督的分级聚类根据肿瘤的组织病理学类型将其分离,并且微阵列的显着性分析确定了包括TP73L(编码p63蛋白)在内的几个基因,相对于这些其他肿瘤,它们在GCTOB中显着高表达。随后使用抗p63抗体在一系列26个GCTOB,25个动脉瘤性骨囊肿,15个软骨母细胞瘤,13个巨细胞修复性肉芽肿,13个软骨粘液样纤维瘤,4个棕色肿瘤,4个纤维性异型增生,53个巨细胞肿瘤中证实了p63的诊断效用组织微阵列中的腱鞘/扩散型巨细胞瘤和385个其他间充质瘤在26例GCTOB中有18例(69%),在15例20%(20%)软骨母细胞瘤中有3例以及在25例(4 %%)的动脉瘤性骨囊肿中存在强p63核染色,而在鉴别诊断中通常不考虑其他任何肿瘤GCTOB诊断显示任何可检测到的p63染色。通常,在骨骼和软组织肿瘤中很少会出现强烈的p63染色。与p63染色的模式相反,大多数软骨母细胞瘤(70%)表现出S-100免疫反应性,而只有少数GCTOB(8%)对S-100具有免疫反应性。这些发现总共表明p63可以用作诊断标志物,以辅助GCTOB的临床诊断。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号